Molecular Epidemiology of Drug Resistance of HIV in India, Pakistan and Vietnam

印度、巴基斯坦和越南艾滋病毒耐药性的分子流行病学

• 批准号: 13576020
• 负责人: YAMAMOTO Naohiko
• 金额: $ 5.89万
• 依托单位: NAGOYA UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2001
• 资助国家: 日本
• 起止时间: 2001 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-13576020/
• 关键词: HIV; AIDS; Drug resistance; Developing countries; Asia and Africa; International Research Collaboration; 発展途上国; アジア; 非B型HIV; インド・パキスタン・ベトナム; インド:パキスタン:ベトナム; プロテアーゼ阻害剤

The progress of combination chemotherapy with HIV-1 reverse transcriptase and protease inhibitors has achieved a lengthen period of suppression of viral replication and clinical efficacy in HIV-1-infected individuals. Nevertheless, presence of HIV-1 resistance resulting from the combination chemotherapy also produces clinical problems, not only for the patients receiving therapy, but for treatment-nave patients in industrialized countries. These multiple-drug resistance viruses in treatment-nave patients are expected to spread m developing Asian and African countries, where lots of patients do not receive the benefit of anti-ADS treatments due to their high cost.It is the aim of this study to show the prevalence of treatment-naive patients in India, where the estimated number of HIV-infected-patients is considered to be the largest in the world, in Pakistan, Vietnam and Kenya Aflica. Protease and reverse transcriptase (RT) coding regions were analyzed in serum samples obtained from 56 treatment-naive patients in India, 17 in Pakistan, 13 in Vietnam, and 34 in Kenya. No primary resistance mutations to RT inhibitors were found among them, but we identified two treatment-naive individuals in 1999 in India, who have primary resistance mutations in protease region G48V and 32A which have been reported to result in a enhance clinically significant loss of response to Saquinavir, Indinavir and Ritonavir. There were high rate (29〜70%) secondaiy resistance mutations to RT inhibitors and Protease inhibitors in the other samples.The result of primary strong resistance mutations on therapy-naive patients in India may have important implications,in setting up initial antiretroviral therapy in developing countries via the United Nations' Global Fund to Fight AIDS.

HIV-1逆转录酶和蛋白酶抑制剂联合化疗的进展已在HIV-1感染者中实现了较长时间的病毒复制抑制和临床疗效，然而，联合化疗也会产生HIV-1耐药性。临床问题不仅针对接受治疗的患者，而且针对工业化国家的未接受治疗的患者。这些在未接受治疗的患者中出现的多重耐药病毒预计将在亚洲和非洲发展中国家传播，而这些国家的许多患者并未接受治疗。的好处由于成本高昂，抗 ADS 治疗受到限制。本研究的目的是显示印度未接受治疗的患者的患病率，该国艾滋病毒感染者的估计人数被认为是世界上最多的。巴基斯坦、越南和肯尼亚非洲对来自印度 56 名未接受治疗的患者、巴基斯坦 17 名、越南 13 名和肯尼亚 34 名患者的血清样本中的蛋白酶和逆转录酶 (RT) 编码区进行了分析，未获得主要耐药突变。其中发现了 RT 抑制剂，但我们于 1999 年在印度发现了两名未接受治疗的个体，他们在蛋白酶区域 G48V 和 32A 中具有主要耐药突变，据报道，这些突变导致对沙奎那韦、茚地那韦和其他样本中存在高比率（29-70%）RT抑制剂和蛋白酶抑制剂的继发耐药突变。原发强耐药突变的结果印度未接受过治疗的患者可能对通过联合国全球抗击艾滋病基金在发展中国家建立初步抗逆转录病毒治疗产生重要影响。

项目成果

Tsuguhiro Kaneda et al.: "Defective HIV-1 provirus found in peripheral Tlymphocytes and granulocytes in an AIDS patient imply viral infection of progenitor cells"AIDS. 15. 939-940 (2001)

Tsuguhiro Kaneda 等人：“在 AIDS 患者的外周 T 淋巴细胞和粒细胞中发现的缺陷 HIV-1 原病毒意味着祖细胞的病毒感染”AIDS。

Junko Hattori et al.: "Prevalence of Infection and Genotypoes of GBV-C/HGV among Homosexual Men"Microbiol.Immunol.. 47(10). 759-763 (2003)

Junko Hattori 等人：“同性恋男性中 GBV-C/HGV 的感染率和基因型”Microbiol.Immunol.. 47(10)。

Muhamad Rafiq Awan et al.: "HIV-1 Subtype (Clades) in Pakistan"Hamdard Medicus. Vol.XLIV, No1. 48-54 (2001)

Muhamad Rafiq Awan 等人：“巴基斯坦的 HIV-1 亚型（分支）”Hamdard Medicus。

Muhmmad Rafiq et al.: "HIV-1 Subtype(clades) in Pakistan"Hamdard Medicus. XLIV. 48-54 (2001)

Muhmmad Rafiq 等人：“巴基斯坦的 HIV-1 亚型（分支）”Hamdard Medicus。

M.Rafiq Awan et al.: "HIV-1 subtype (Clades) in Pakistan"Hamdard Medicus (2001). XLIV(1). 48-54 (2001)

M.Rafiq Awan 等人：“巴基斯坦的 HIV-1 亚型（分支）”Hamdard Medicus (2001)。